The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...
(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...
The U.S. Centers for Disease Control and Prevention on Friday upheld the role of vaccines in offering protection against ...
Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces ...
Affirm Holdings, Inc. , the payment network that empowers consumers and helps merchants drive growth, today announced that Rob O'Hare, CFO of Affirm, will participate in a fireside chat to answer a ...
Dynaprice.com, Inc. today announced definitive agreement and completion of all closing conditions to merge with Dinamo Acquisition Corporation. Through this merger, control of the company passes to a ...
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.
New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...
Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., JD.com, and AstraZeneca are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical ...
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results